Plantibodies 市场 - 全球产业规模、份额、趋势、机会和预测，按基因改造作物、技术、应用、最终用户、地区和竞争细分，2019-2029F

2023 年全球Plantibodies 市场估值为5,065 万美元，预计在预测期内将出现令人印象深刻的成长，到2029 年复合年增长率为8.08%。製程生产特异性抗体。与传统生产方法相比，这些植物源抗体具有潜在优势，例如成本效益、可扩展性以及降低人类或动物病原体污染的风险。植物体可能为从癌症到传染病等多种疾病提供新的治疗选择。

主要市场驱动因素

生物技术的进步

成本效益

可扩充性和灵活性

降低污染风险

主要市场挑战

基因工程的复杂性

纯化和下游加工

主要市场趋势

广泛的治疗应用

监管支持和接受

细分市场洞察

基因改造作物见解

最终使用者见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球 Plantibodies 市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 依基因改造作物（烟草、豆类、谷物、种子块茎、水果蔬菜、其他）
  • 按技术（常规方法、组织培养、有性杂交育种、基因改造种子、其他）
  • 按应用（自体免疫疾病、癌症、传染病、免疫、牙科、其他）
  • 按最终用户（生物技术製药公司、学术研究机构、其他）
  • 按地区
  • 按公司划分 (2023)
• 市场地图

第 6 章：北美 Plantibodies 市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 作者：基因改造作物
  • 依技术
  • 按申请
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲 Plantibodies 市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按基因改造作物
  • 依技术
  • 按申请
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太植物抗体市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按基因改造作物
  • 依技术
  • 按申请
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲 Plantibodies 市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按基因改造作物
  • 依技术
  • 按申请
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲植物抗体市场展望

• 市场规模预测
  • 按价值
• 市占率预测
  • 按基因改造作物
  • 依技术
  • 按申请
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势发展

• 併购（如有）
• 产品发布（如有）
• 最近的发展

第 13 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第14章：竞争格局

• PlantForm Corporation
• Planet Biotechnology Inc.
• iBio, Inc.
• Mapp Biopharmaceutical, Inc. (Allergan, Inc.)
• Medicago Inc.
• NOMAD Bioscience GmbH
• Ventria Bioscience Inc.
• Agrisera AB
• Creative Biolabs, Inc.
• Protalix BioTherapeutics Inc.

第 15 章：策略建议

第 16 章：关于我们免责声明

Global Plantibodies Market was valued at USD 50.65 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.08% through 2029. Plantibodies utilize genetically modified plants, such as tobacco or maize, to produce specific antibodies through biotechnology processes. These plant-derived antibodies hold potential advantages over traditional production methods, such as cost-effectiveness, scalability, and reduced risk of contamination with human or animal pathogens. Plantibodies may offer novel therapeutic options for conditions ranging from cancer to infectious diseases.

Key Market Drivers

Advancements in Biotechnology

Technological advancements in biotechnology have ushered in a new era in the production of plantibodies, marking a significant leap forward in the field of biopharmaceuticals. Through innovative techniques and methodologies, scientists have unlocked the potential of plants as bioreactors for the expression of specific antibodies or antibody-like proteins. This breakthrough has revolutionized the landscape of antibody production, offering a sustainable and cost-effective alternative to traditional manufacturing methods.

One of the key advancements driving the production of plantibodies is the development of genetic engineering tools that enable precise manipulation of plant genomes. By introducing genes encoding desired antibodies into plant cells, researchers can harness the natural machinery of plants to produce therapeutic proteins. These genetic modifications can be tailored to optimize protein expression levels, enhance protein stability, and facilitate downstream purification processes, resulting in higher yields of high-quality plantibodies. Advancements in plant biotechnology have led to the creation of novel plant expression systems that are specifically designed for the production of biopharmaceuticals. These engineered plant systems offer improved scalability, faster production timelines, and enhanced protein expression levels compared to conventional plant-based expression platforms. By leveraging these cutting-edge technologies, biopharmaceutical companies can expedite the development and commercialization of plantibody-based therapeutics.

Cost-Effectiveness

Plantibodies represent a transformative advancement in biopharmaceutical production, offering a cost-effective alternative to conventional methods like mammalian cell culture or microbial fermentation. Through the innovative use of plants as bioreactors, plantibody production circumvents the substantial expenses typically associated with traditional production systems. The inherent cost advantages of plantibodies stem from several key factors. Plants offer a readily available and renewable resource, eliminating the need for costly infrastructure and facilities associated with mammalian cell culture or microbial fermentation. Unlike these systems, which often require specialized laboratories and controlled environments, plantibody production can be conducted in greenhouses or growth chambers, significantly reducing overhead costs.

Plants require minimal nutrient inputs and can be cultivated using inexpensive growth media, further driving down production costs. Unlike mammalian cell culture, which relies on complex nutrient formulations and serum supplements, plants can thrive on simple nutrient solutions, making plantibody production inherently more economical.

Scalability and Flexibility

Plants offer an unparalleled platform to produce plantibodies, characterized by scalability and flexibility that far surpass conventional mammalian cell culture systems. The inherent biological properties of plants, coupled with advancements in biotechnology, make them ideal bioreactors for meeting the growing demand for plantibodies. One of the most significant advantages of using plants for plantibody production is their scalability. Unlike mammalian cell culture systems, which often have limited scalability due to the requirement for specialized equipment and controlled environments, plants can be cultivated in large quantities under relatively simple conditions. By leveraging modern agricultural practices and greenhouse technologies, plantibody production can be rapidly scaled up to meet the needs of clinical trials and commercialization.

Reduced Risk of Contamination

The production of plantibodies presents a revolutionary approach with inherent biosafety and biosecurity advantages, distinguishing it from traditional bioreactor-based production systems. Plants serve as natural bioreactors devoid of human or animal pathogens, inherently minimizing the risk of contamination with adventitious agents that may compromise the safety and integrity of biopharmaceutical products. One of the primary advantages of plantibody production lies in the absence of human or animal pathogens within plant hosts. Unlike mammalian cell culture or microbial fermentation systems, which require rigorous containment measures to prevent the introduction or spread of pathogens, plants inherently lack the capacity to harbor such contaminants. As a result, plantibody production eliminates the potential risk of contamination with viruses, prions, or other adventitious agents that may pose safety concerns for biopharmaceutical products.

This inherent biosafety advantage is particularly crucial in the context of pharmaceutical manufacturing, where the safety and purity of therapeutic proteins are paramount. Contamination with human or animal pathogens not only jeopardizes the efficacy of biopharmaceutical products but also poses significant risks to patient health and safety. By utilizing plants as bioreactors, plantibody production minimizes these risks, ensuring the integrity and safety of the final product.

Key Market Challenges

Complexity of Genetic Engineering

One of the primary challenges in the global plantibodies market is the complexity of genetic engineering required for the development of plantibodies. While plants offer a promising platform for producing therapeutic antibodies, the process of introducing and expressing antibody genes in plant cells can be intricate and technically demanding. Genetic modification techniques such as agrobacterium-mediated transformation or viral vector delivery require specialized expertise and infrastructure, limiting the accessibility of plantibody technology to research laboratories or biopharmaceutical companies with the necessary resources.

Optimizing expression levels, glycosylation patterns, and post-translational modifications of plantibodies to achieve desired therapeutic properties can be challenging. Variability in plant gene expression and glycosylation machinery adds another layer of complexity, necessitating extensive characterization and optimization to ensure consistent product quality and efficacy. Overcoming these technical hurdles and streamlining the genetic engineering process is essential for the widespread adoption and commercialization of plantibody-based therapeutics.

Purification and Downstream Processing

Another significant challenge facing the global plantibodies market is the purification and downstream processing of plantibodies to obtain high-purity, pharmaceutical-grade products. Plant tissues contain a complex mixture of proteins, lipids, carbohydrates, and secondary metabolites, making the purification of recombinant antibodies from plant extracts a challenging task. Traditional purification methods such as protein A affinity chromatography, commonly used for mammalian cell-derived antibodies, may not be suitable for plantibodies due to differences in glycosylation and protein structure.

Developing robust and efficient purification strategies tailored to plantibodies is essential to ensure product quality, safety, and scalability. Innovative purification technologies such as lectin affinity chromatography, membrane filtration, and precipitation methods are being explored to overcome these challenges. Optimizing extraction protocols, buffer formulations, and process parameters to minimize non-specific binding and maximize antibody recovery is critical for achieving high yields and purity levels in plantibody purification processes.

Key Market Trends

Broad Therapeutic Applications

Plantibodies, with their unique properties and customizable nature, represent a groundbreaking advancement in biopharmaceuticals, holding tremendous promise across various therapeutic domains. Their ability to target specific antigens with high affinity and specificity makes them invaluable tools for precision medicine and personalized healthcare, opening up novel treatment avenues for patients with diverse medical conditions.

One of the most promising applications of plantibodies lies in cancer therapy. These plant-derived antibodies can be engineered to selectively target tumor-specific antigens, facilitating precise and targeted destruction of cancer cells while sparing healthy tissues. Plantibodies offer potential advantages over conventional cancer therapies, including reduced toxicity, improved efficacy, and enhanced tumor penetration, thereby offering hope for more effective and personalized cancer treatment strategies.

Regulatory Support and Acceptance

Regulatory agencies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are increasingly recognizing plantibodies as a promising and viable biopharmaceutical production platform. This acknowledgment is underpinned by a mounting body of scientific evidence attesting to the safety, efficacy, and quality of plantibody-based therapeutics, paving the way for their regulatory acceptance and facilitating their clinical development and commercialization.

The FDA and EMA, as well as other regulatory authorities worldwide, play a pivotal role in evaluating the safety and efficacy of new pharmaceutical products, ensuring that they meet stringent standards for quality, purity, and potency before they can be approved for clinical use. In recent years, these agencies have shown a growing interest in plantibodies as a novel and innovative approach to biopharmaceutical production, recognizing their potential to address unmet medical needs and improve patient outcomes.

Segmental Insights

Transgenic Crop Insights

Based on the transgenic crop, tobacco emerge as a dominant player due to their unique advantages in biopharmaceutical production. Tobacco plants, particularly Nicotiana species, have garnered significant attention and adoption for the production of plantibodies, primarily owing to their well-established biotechnology infrastructure, rapid growth cycle, and high biomass yield. Tobacco plants offer several distinct characteristics that make them highly suitable for plantibody production. Tobacco plants have been extensively studied and genetically engineered over decades, making them one of the most well-characterized plant systems for recombinant protein expression. This extensive knowledge base facilitates the efficient engineering and optimization of tobacco plants for the production of therapeutic antibodies with desired properties.

Tobacco plants exhibit a rapid growth cycle and high biomass yield, allowing for large-scale cultivation and production of plantibodies within a relatively short timeframe. This scalability is crucial for meeting the demand for therapeutic antibodies in clinical trials and commercial production, ensuring a reliable and cost-effective supply of plantibody-based therapeutics.

End User Insights

Based on the end user segment, biotechnology and pharmaceutical companies emerge as dominant players, driving innovation, research, and commercialization efforts in plantibody-based therapeutics. These companies, ranging from established pharmaceutical giants to emerging biotech startups, leverage their expertise, resources, and infrastructure to advance the development and application of plantibodies across diverse therapeutic areas.

Biotechnology and pharmaceutical companies play a central role in shaping the global plantibodies market through their substantial investments in research and development (RD) activities focused on plant-based biopharmaceutical production. These companies possess extensive knowledge and experience in bioprocess engineering, genetic engineering, and protein expression technologies, enabling them to optimize plantibody production platforms for scalability, efficiency, and product quality. Biotechnology and pharmaceutical companies have the necessary financial resources and capabilities to fund large-scale clinical trials, regulatory submissions, and commercialization efforts for plantibody-based therapeutics. Their established infrastructure for drug discovery, development, and manufacturing provides a solid foundation for accelerating the translation of plantibody research into clinical applications and ultimately, commercial products.

Regional Insights

North America emerges as a dominant force, spearheading innovation, research, and commercialization efforts in plantibody-based therapeutics. The region's leadership in the global plantibodies market can be attributed to several key factors that contribute to its prominence and influence in this burgeoning field.

North America boasts a robust and mature biotechnology and pharmaceutical industry, comprising a diverse ecosystem of companies, research institutes, academic institutions, and government agencies dedicated to advancing biopharmaceutical innovation. With world-renowned biotechnology hubs such as the San Francisco Bay Area, Boston-Cambridge, and San Diego, North America serves as a hotbed for cutting-edge research and development in plantibodies. The region benefits from a conducive regulatory environment and supportive government policies that foster innovation and investment in biopharmaceuticals. Regulatory agencies such as the US Food and Drug Administration (FDA) and Health Canada have established clear pathways for the development, approval, and commercialization of biologic drugs, including plantibody-based therapeutics, thereby facilitating market entry and growth.

Key Market Players

PlantForm Corporation

Planet Biotechnology Inc.

iBio, Inc.

Mapp Biopharmaceutical, Inc. (Allergan, Inc.)

Medicago Inc.

NOMAD Bioscience GmbH

Ventria Bioscience Inc.

Agrisera AB

Creative Biolabs, Inc.

Protalix BioTherapeutics Inc.

Report Scope:

In this report, the Global Plantibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plantibodies Market,By Transgenic Crop:

• Tobacco
• Legumes
• Cereals
• Seeds Tubers
• Fruits Vegetables
• Others

Plantibodies Market,By Technique:

• Conventional Method
• Tissue Culture
• Breeding Sexual Crossing
• Transgenic Seeds
• Others

Plantibodies Market,By Application:

• Autoimmune Diseases
• Cancer
• Infectious Diseases
• Immunization
• Dentistry
• Others

Plantibodies Market,By End User:

• Biotechnology Pharmaceutical Companies
• Academic Research Institutes
• Others

Plantibodies Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plantibodies Market.

Available Customizations:

Global Plantibodies market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validations
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Plantibodies Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Transgenic Crop (Tobacco, Legumes, Cereals, Seeds Tubers, Fruits Vegetables, Others)
  • 5.2.2.By Technique (Conventional Method, Tissue Culture, Breeding Sexual Crossing, Transgenic Seeds, Others)
  • 5.2.3.By Application (Autoimmune Diseases, Cancer, Infectious Diseases, Immunization, Dentistry, Others)
  • 5.2.4.By End User (Biotechnology Pharmaceutical Companies, Academic Research Institutes, Others)
  • 5.2.5.By Region
  • 5.2.6.By Company (2023)
• 5.3.Market Map

6.North America Plantibodies Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.ByTransgenic Crop
  • 6.2.2.By Technique
  • 6.2.3.By Application
  • 6.2.4.By End User
  • 6.2.5.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States Plantibodies Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Transgenic Crop
      • 6.3.1.2.2.By Technique
      • 6.3.1.2.3.By Application
      • 6.3.1.2.4.By End User
  • 6.3.2.Canada Plantibodies Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Transgenic Crop
      • 6.3.2.2.2.By Technique
      • 6.3.2.2.3.By Application
      • 6.3.2.2.4.By End User
  • 6.3.3.Mexico Plantibodies Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Transgenic Crop
      • 6.3.3.2.2.By Technique
      • 6.3.3.2.3.By Application
      • 6.3.3.2.4.By End User

7.Europe Plantibodies Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Transgenic Crop
  • 7.2.2.By Technique
  • 7.2.3.By Application
  • 7.2.4.By End User
  • 7.2.5.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.Germany Plantibodies Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Transgenic Crop
      • 7.3.1.2.2.By Technique
      • 7.3.1.2.3.By Application
      • 7.3.1.2.4.By End User
  • 7.3.2.United Kingdom Plantibodies Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Transgenic Crop
      • 7.3.2.2.2.By Technique
      • 7.3.2.2.3.By Application
      • 7.3.2.2.4.By End User
  • 7.3.3.Italy Plantibodies Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecasty
      • 7.3.3.2.1.By Transgenic Crop
      • 7.3.3.2.2.By Technique
      • 7.3.3.2.3.By Application
      • 7.3.3.2.4.By End User
  • 7.3.4.France Plantibodies Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Transgenic Crop
      • 7.3.4.2.2.By Technique
      • 7.3.4.2.3.By Application
      • 7.3.4.2.4.By End User
  • 7.3.5.Spain Plantibodies Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Transgenic Crop
      • 7.3.5.2.2.By Technique
      • 7.3.5.2.3.By Application
      • 7.3.5.2.4.By End User

8.Asia-Pacific Plantibodies Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Transgenic Crop
  • 8.2.2.By Technique
  • 8.2.3.By Application
  • 8.2.4.By End User
  • 8.2.5.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China Plantibodies Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Transgenic Crop
      • 8.3.1.2.2.By Technique
      • 8.3.1.2.3.By Application
      • 8.3.1.2.4.By End User
  • 8.3.2.India Plantibodies Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Transgenic Crop
      • 8.3.2.2.2.By Technique
      • 8.3.2.2.3.By Application
      • 8.3.2.2.4.By End User
  • 8.3.3.Japan Plantibodies Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Transgenic Crop
      • 8.3.3.2.2.By Technique
      • 8.3.3.2.3.By Application
      • 8.3.3.2.4.By End User
  • 8.3.4.South Korea Plantibodies Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Transgenic Crop
      • 8.3.4.2.2.By Technique
      • 8.3.4.2.3.By Application
      • 8.3.4.2.4.By End User
  • 8.3.5.Australia Plantibodies Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Transgenic Crop
      • 8.3.5.2.2.By Technique
      • 8.3.5.2.3.By Application
      • 8.3.5.2.4.By End User

9.South America Plantibodies Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Transgenic Crop
  • 9.2.2.By Technique
  • 9.2.3.By Application
  • 9.2.4.By End User
  • 9.2.5.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Plantibodies Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Transgenic Crop
      • 9.3.1.2.2.By Technique
      • 9.3.1.2.3.By Application
      • 9.3.1.2.4.By End User
  • 9.3.2.Argentina Plantibodies Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Transgenic Crop
      • 9.3.2.2.2.By Technique
      • 9.3.2.2.3.By Application
      • 9.3.2.2.4.By End User
  • 9.3.3.Colombia Plantibodies Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Transgenic Crop
      • 9.3.3.2.2.By Technique
      • 9.3.3.2.3.By Application
      • 9.3.3.2.4.By End User

10.Middle East and Africa Plantibodies Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Transgenic Crop
  • 10.2.2.By Technique
  • 10.2.3.By Application
  • 10.2.4.By End User
  • 10.2.5.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Plantibodies Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Transgenic Crop
      • 10.3.1.2.2.By Technique
      • 10.3.1.2.3.By Application
      • 10.3.1.2.4.By End User
  • 10.3.2.Saudi Arabia Plantibodies Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Transgenic Crop
      • 10.3.2.2.2.By Technique
      • 10.3.2.2.3.By Application
      • 10.3.2.2.4.By End User
  • 10.3.3.UAE Plantibodies Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Transgenic Crop
      • 10.3.3.2.2.By Technique
      • 10.3.3.2.3.By Application
      • 10.3.3.2.4.By End User

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Merger Acquisition (If Any)
• 12.2.Product Launches (If Any)
• 12.3.Recent Developments

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Products

14.Competitive Landscape

• 14.1.PlantForm Corporation
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Products Services
  • 14.1.4.Financials (As Reported)
  • 14.1.5.Recent Developments
  • 14.1.6.Key Personnel Details
  • 14.1.7.SWOT Analysis
• 14.2.Planet Biotechnology Inc.
• 14.3.iBio, Inc.
• 14.4.Mapp Biopharmaceutical, Inc. (Allergan, Inc.)
• 14.5.Medicago Inc.
• 14.6.NOMAD Bioscience GmbH
• 14.7.Ventria Bioscience Inc.
• 14.8.Agrisera AB
• 14.9.Creative Biolabs, Inc.
• 14.10.Protalix BioTherapeutics Inc.

15.Strategic Recommendations

16.About Us Disclaimer